Myovant Sciences Ltd (MYOV)

[stockguard]

Myovant conference call tomorrow on Phase 3 relugolix data in endometriosis
Jun. 22, 2020 4:10 PM ET|About: Myovant Sciences Ltd. (MYOV)

Myovant Sciences (NYSE:MYOV) will host a webcast and conference call tomorrow, June 23, at 8:30 am ET to discuss results from a Phase 3 clinical trial, SPIRIT 1, evaluating once-daily relugolix combo therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis.

Shares up 2% after hours.

The webcast and conference call to discuss the data will be held on Tuesday, June 23, 2020 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. To participate in the live conference call, please dial 1-800-532-3746 for domestic callers and [phone] for international callers. A live webcast of the conference call will also be available on the investor relations page of Myovant's website at investors.myovant.com and will remain archived on Myovant's website for at least 30 days.